Therapeutic glucocorticoids have been widely used in rheumatic diseases since they became available over 60 years ago. Despite the advent of more specific biologic therapies, a notable proportion of individuals with chronic rheumatic diseases continue to be treated with these drugs. Glucocorticoids are powerful, broad-spectrum anti-inflammatory agents, but their use is complicated by an equally broad range of adverse effects. The specific cellular mechanisms by which glucocorticoids have their therapeutic action have been difficult to identify, and attempts to develop more selective drugs on the basis of the action of glucocorticoids have proven difficult. The actions of glucocorticoids seem to be highly cell-type and context dependent. Despite emerging data on the effect of tissue-specific manipulation of glucocorticoid receptors in mouse models of inflammation, the cell types and intracellular targets of glucocorticoids in rheumatic diseases have not been fully identified. Although showing some signs of decline, the use of systemic glucocorticoids in rheumatology is likely to continue to be widespread, and careful consideration is required by rheumatologists to balance the beneficial effects and deleterious effects of these agents.
Therapeutic glucocorticoids are powerful, broad-spectrum anti-inflammatory agents that are limited by a wide range of adverse effects.
The specific mechanisms of action by which glucocorticoids mediate anti-inflammatory effects in rheumatic diseases are still unclear, hindering the development of novel therapeutic agents.
Approaches to the study of glucocorticoid actions have been complicated by the widespread use of animal tissues and transformed cell lines rather than human primary cells.
The development of novel glucocorticoids that ‘dissociate’ molecular transrepression from transactivation have proven difficult; however, one such dissociated glucocorticoid agonist is undergoing clinical trials in patients with inflammatory arthritis.
The use of genetically modified mice with altered glucocorticoid sensitivity in specific tissues and/or transcriptomic studies using primary human cells are promising approaches for defining cellular and molecular glucocorticoid targets.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
Accrual of organ damage in Behçet’s syndrome: trajectory, associated factors, and impact on patients’ quality of life over a 2-year prospective follow-up study
Arthritis Research & Therapy Open Access 17 November 2022
Seminars in Immunopathology Open Access 29 April 2022
Subscribe to Nature+
Get immediate online access to Nature and 55 other Nature journal
Subscribe to Journal
Get full journal access for 1 year
only $6.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Hench, P. S. et al. The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone; compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis. Proc. Staff Meet. Mayo Clin. 24, 181–197 (1949).
Black, R. J. et al. Factors associated with oral glucocorticoid use in patients with rheumatoid arthritis: a drug use study from a prospective national biologics registry. Arthritis Res. Ther. 19, 253 (2017).
van Staa, T. P. et al. Use of oral corticosteroids in the United Kingdom. QJM 93, 105–111 (2000).
Overman, R. A., Yeh, J. Y. & Deal, C. L. Prevalence of oral glucocorticoid usage in the United States: a general population perspective. Arthritis Care Res. 65, 294–298 (2013).
Lillegraven, S. et al. Immunosuppressive treatment and the risk of diabetes in rheumatoid arthritis. PLoS One 14, e0210459 (2019).
Strehl, C. et al. Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force. Ann. Rheum. Dis. 75, 952–957 (2016).
van Staa, T. P., Leufkens, H. G., Abenhaim, L., Zhang, B. & Cooper, C. Use of oral corticosteroids and risk of fractures. J. Bone Miner. Res. 15, 993–1000 (2000).
Hardy, R. S., Zhou, H., Seibel, M. J. & Cooper, M. S. Glucocorticoids and bone: consequences of endogenous and exogenous excess and replacement therapy. Endocr. Rev. 39, 519–548 (2018).
Black, R. J. et al. A survey of glucocorticoid adverse effects and benefits in rheumatic diseases: the patient perspective. J. Clin. Rheumatol. 23, 416–420 (2017).
Costello, R., Patel, R., Humphreys, J., McBeth, J. & Dixon, W. G. Patient perceptions of glucocorticoid side effects: a cross-sectional survey of users in an online health community. BMJ Open 7, e014603 (2017).
Cooper, M. S. & Stewart, P. M. Corticosteroid insufficiency in acutely ill patients. N. Engl. J. Med. 348, 727–734 (2003).
Fuller, P. J., Lim-Tio, S. S. & Brennan, F. E. Specificity in mineralocorticoid versus glucocorticoid action. Kidney Int. 57, 1256–1264 (2000).
Bledsoe, R. K. et al. Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition. Cell 110, 93–105 (2002).
Gomez-Sanchez, E. & Gomez-Sanchez, C. E. The multifaceted mineralocorticoid receptor. Compr. Physiol. 4, 965–994 (2014).
Hardy, R. S. et al. 11 beta-hydroxysteroid dehydrogenase type 1 regulates synovitis, joint destruction, and systemic bone loss in chronic polyarthritis. J. Autoimmun. 92, 104–113 (2018).
Coutinho, A. E. et al. 11β-hydroxysteroid dehydrogenase type 1, but not type 2, deficiency worsens acute inflammation and experimental arthritis in mice. Endocrinology 153, 234–240 (2012).
Jones, I. A., Togashi, R., Wilson, M. L., Heckmann, N. & Vangsness, C. T. Jr. Intra-articular treatment options for knee osteoarthritis. Nat. Rev. Rheumatol. 15, 77–90 (2019).
Buttgereit, F. et al. Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial. Lancet 371, 205–214 (2008).
Buttgereit, F. et al. Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2). Ann. Rheum. Dis. 72, 204–210 (2013).
Wu, T. et al. Timing of glucocorticoid administration determines severity of lipid metabolism and behavioral effects in rats. Chronobiol. Int. 34, 78–92 (2017).
Caratti, G. et al. REVERBa couples the circadian clock to hepatic glucocorticoid action. J. Clin. Invest. 128, 4454–4471 (2018).
Kalafatakis, K. et al. Ultradian rhythmicity of plasma cortisol is necessary for normal emotional and cognitive responses in man. Proc. Natl Acad. Sci. USA 115, E4091–E4100 (2018).
Luhder, F. & Reichardt, H. M. Novel drug delivery systems tailored for improved administration of glucocorticoids. Int. J. Mol. Sci. 18, E1836 (2017).
Conaghan, P. G. et al. Brief report: a phase IIB trial of a novel extended-release microsphere formulation of triamcinolone acetonide for intraarticular injection in knee osteoarthritis. Arthritis Rheumatol. 70, 204–211 (2018).
Joshi, N. et al. Towards an arthritis flare-responsive drug delivery system. Nat. Commun. 9, 1275 (2018).
Cain, D. W. & Cidlowski, J. A. Immune regulation by glucocorticoids. Nat. Rev. Immunol. 17, 233–247 (2017).
Oakley, R. H., Webster, J. C., Jewell, C. M., Sar, M. & Cidlowski, J. A. Immunocytochemical analysis of the glucocorticoid receptor alpha isoform (GRα) using GRα-specific antibody. Steroids 64, 742–751 (1999).
Kino, T., Su, Y. A. & Chrousos, G. P. Human glucocorticoid receptor isoform β: recent understanding of its potential implications in physiology and pathophysiology. Cell Mol. Life Sci. 66, 3435–3448 (2009).
Derijk, R. H. et al. A human glucocorticoid receptor gene variant that increases the stability of the glucocorticoid receptor β-isoform mRNA is associated with rheumatoid arthritis. J. Rheumatol. 28, 2383–2388 (2001).
Oakley, R. H. et al. Glucocorticoid receptor isoform-specific regulation of development, circadian rhythm, and inflammation in mice. FASEB J. 32, 5258–5271 (2018).
Cao, Y. et al. Glucocorticoid receptor translational isoforms underlie maturational stage-specific glucocorticoid sensitivities of dendritic cells in mice and humans. Blood 121, 1553–1562 (2013).
Hua, G., Paulen, L. & Chambon, P. GR SUMOylation and formation of an SUMO-SMRT/NCoR1-HDAC3 repressing complex is mandatory for GC-induced IR nGRE-mediated transrepression. Proc. Natl Acad. Sci. USA 113, E626–E634 (2016).
Wilkinson, L., Verhoog, N. & Louw, A. Novel role for receptor dimerization in post-translational processing and turnover of the GRα. Sci. Rep. 8, 14266 (2018).
Kino, T. & Chrousos, G. P. Acetylation-mediated epigenetic regulation of glucocorticoid receptor activity: circadian rhythm-associated alterations of glucocorticoid actions in target tissues. Mol. Cell. Endocrinol. 336, 23–30 (2011).
Nahar, J. et al. Rapid nongenomic glucocorticoid actions in male mouse hypothalamic neuroendocrine cells are dependent on the nuclear glucocorticoid receptor. Endocrinology 156, 2831–2842 (2015).
Deng, Q. et al. Rapid glucocorticoid feedback inhibition of acth secretion involves ligand-dependent membrane association of glucocorticoid receptors. Endocrinology 156, 3215–3227 (2015).
Cooper, M. S., Zhou, H. & Seibel, M. J. Selective glucocorticoid receptor agonists: glucocorticoid therapy with no regrets? J. Bone Miner. Res. 27, 2238–2241 (2012).
Abraham, S. M. et al. Antiinflammatory effects of dexamethasone are partly dependent on induction of dual specificity phosphatase 1. J. Exp. Med. 203, 1883–1889 (2006).
Vettorazzi, S. et al. Glucocorticoids limit acute lung inflammation in concert with inflammatory stimuli by induction of SphK1. Nat. Commun. 6, 7796 (2015).
Yang, Y. H. et al. Modulation of inflammation and response to dexamethasone by annexin 1 in antigen-induced arthritis. Arthritis Rheum. 50, 976–984 (2004).
Reichardt, H. M. et al. DNA binding of the glucocorticoid receptor is not essential for survival. Cell 93, 531–541 (1998).
Kleiman, A. et al. Glucocorticoid receptor dimerization is required for survival in septic shock via suppression of interleukin-1 in macrophages. FASEB J. 26, 722–729 (2012).
Rauch, A. et al. Glucocorticoids suppress bone formation by attenuating osteoblast differentiation via the monomeric glucocorticoid receptor. Cell Metab. 11, 517–531 (2010).
Sacta, M. A., Chinenov, Y. & Rogatsky, I. Glucocorticoid signaling: an update from a genomic perspective. Annu. Rev. Physiol. 78, 155–180 (2016).
Lim, H. W. et al. Genomic redistribution of GR monomers and dimers mediates transcriptional response to exogenous glucocorticoid in vivo. Genome Res. 25, 836–844 (2015).
Love, M. I. et al. Role of the chromatin landscape and sequence in determining cell type-specific genomic glucocorticoid receptor binding and gene regulation. Nucleic Acids Res. 45, 1805–1819 (2017).
Wang, C. et al. Extensive epigenomic integration of the glucocorticoid response in primary human monocytes and in vitro derived macrophages. Sci. Rep. 9, 2772 (2019).
Franco, L. M. et al. Immune regulation by glucocorticoids can be linked to cell type-dependent transcriptional responses. J. Exp. Med. 216, 384–406 (2019).
Galon, J. et al. Gene profiling reveals unknown enhancing and suppressive actions of glucocorticoids on immune cells. FASEB J. 16, 61–71 (2002).
Clayton, S. A., Jones, S. W., Kurowska-Stolarska, M. & Clark, A. R. The role of microRNAs in glucocorticoid action. J. Biol. Chem. 293, 1865–1874 (2018).
Whirledge, S. & DeFranco, D. B. Glucocorticoid signaling in health and disease: insights from tissue-specific GR knockout mice. Endocrinology 159, 46–64 (2018).
Baschant, U. et al. Glucocorticoid therapy of antigen-induced arthritis depends on the dimerized glucocorticoid receptor in T cells. Proc. Natl Acad. Sci. USA 108, 19317–19322 (2011).
Koenen, M. et al. Glucocorticoid receptor in stromal cells is essential for glucocorticoid-mediated suppression of inflammation in arthritis. Ann. Rheum. Dis. 77, 1610–1618 (2018).
Tuckermann, J. P. et al. Macrophages and neutrophils are the targets for immune suppression by glucocorticoids in contact allergy. J. Clin. Invest. 117, 1381–1390 (2007).
Tu, J. et al. Endogenous glucocorticoid signaling in chondrocytes attenuates joint inflammation and damage. FASEB J. 32, 478–487 (2018).
Buttgereit, F. et al. Transgenic disruption of glucocorticoid signaling in mature osteoblasts and osteocytes attenuates K/B×N mouse serum-induced arthritis in vivo. Arthritis Rheum. 60, 1998–2007 (2009).
Frank, M. G., Thompson, B. M., Watkins, L. R. & Maier, S. F. Glucocorticoids mediate stress-induced priming of microglial pro-inflammatory responses. Brain Behav. Immun. 26, 337–345 (2012).
Briot, K., Geusens, P., Em Bultink, I., Lems, W. F. & Roux, C. Inflammatory diseases and bone fragility. Osteoporos. Int. 28, 3301–3314 (2017).
Weinstein, R. S., Jilka, R. L., Parfitt, A. M. & Manolagas, S. C. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J. Clin. Invest 102, 274–282 (1998).
Piemontese, M., Xiong, J., Fujiwara, Y., Thostenson, J. D. & O’Brien, C. A. Cortical bone loss caused by glucocorticoid excess requires RANKL production by osteocytes and is associated with reduced OPG expression in mice. Am. J. Physiol. Endocrinol. Metab. 311, E587–E593 (2016).
Lofberg, E. et al. Effects of high doses of glucocorticoids on free amino acids, ribosomes and protein turnover in human muscle. Eur. J. Clin. Invest. 32, 345–353 (2002).
Wang, R., Jiao, H., Zhao, J., Wang, X. & Lin, H. Glucocorticoids enhance muscle proteolysis through a myostatin-dependent pathway at the early stage. PLoS One 11, e0156225 (2016).
Schakman, O. et al. Insulin-like growth factor-I gene transfer by electroporation prevents skeletal muscle atrophy in glucocorticoid-treated rats. Endocrinology 146, 1789–1797 (2005).
Lemmey, A. B. et al. Muscle loss following a single high-dose intramuscular injection of corticosteroids to treat disease flare in patients with rheumatoid arthritis. Eur. J. Rheumatol. 5, 160–164 (2018).
Hilton-Jones, D. Diagnosis and treatment of inflammatory muscle diseases. J. Neurol. Neurosurg. Psychiatry 74, ii25–ii31 (2003).
Tomas, F. M., Munro, H. N. & Young, V. R. Effect of glucocorticoid administration on the rate of muscle protein breakdown in vivo in rats, as measured by urinary excretion of Nτ-methylhistidine. Biochem. J. 178, 139–146 (1979).
Wang, H., Kubica, N., Ellisen, L. W., Jefferson, L. S. & Kimball, S. R. Dexamethasone represses signaling through the mammalian target of rapamycin in muscle cells by enhancing expression of REDD1. J. Biol. Chem. 281, 39128–39134 (2006).
Hu, Z., Wang, H., Lee, I. H., Du, J. & Mitch, W. E. Endogenous glucocorticoids and impaired insulin signaling are both required to stimulate muscle wasting under pathophysiological conditions in mice. J. Clin. Invest. 119, 3059–3069 (2009).
Bodine, S. C. et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 294, 1704–1708 (2001).
Qin, W. et al. Identification of functional glucocorticoid response elements in the mouse foxo1 promoter. Biochem. Biophys. Res. Commun. 450, 979–983 (2014).
Cho, J. E., Fournier, M., Da, X. Y. & Lewis, M. I. Time course expression of Foxo transcription factors in skeletal muscle following corticosteroid administration. J. Appl. Physiol. 108, 137–145 (2010).
Peckett, A. J., Wright, D. C. & Riddell, M. C. The effects of glucocorticoids on adipose tissue lipid metabolism. Metabolism 60, 1500–1510 (2011).
Manolopoulos, K. N., O’Reilly, M. W., Bujalska, I. J., Tomlinson, J. W. & Arlt, W. Acute hypercortisolemia exerts depot-specific effects on abdominal and femoral adipose tissue function. J. Clin. Endocrinol. Metab. 102, 1091–1101 (2017).
Brennan-Speranza, T. C. et al. Osteoblasts mediate the adverse effects of glucocorticoids on fuel metabolism. J. Clin. Invest. 122, 4172–4189 (2012).
Lee, N. K. et al. Endocrine regulation of energy metabolism by the skeleton. Cell 130, 456–469 (2007).
Steinbuch, M., Youket, T. E. & Cohen, S. Oral glucocorticoid use is associated with an increased risk of fracture. Osteoporos. Int. 15, 323–328 (2004).
Desmet, S. J. & De Bosscher, K. Glucocorticoid receptors: finding the middle ground. J. Clin. Invest. 127, 1136–1145 (2017).
Safy, M. et al. Efficacy and safety of selective glucocorticoid receptor modulators in comparison to glucocorticoids in arthritis, a systematic review. PLoS One 12, e0188810 (2017).
Stock, T., Fleishaker, D., Wang, X., Mukherjee, A. & Mebus, C. Improved disease activity with fosdagrocorat (PF-04171327), a partial agonist of the glucocorticoid receptor, in patients with rheumatoid arthritis: a phase 2 randomized study. Int. J. Rheum. Dis. 20, 960–970 (2017).
Buttgereit et al. Fosdagrocorat (PF-04171327) versus prednisone or placebo in rheumatoid arthritis: a randomised, double-blind, multicentre, phase IIb study. RMD Open 5, e000889. eCollection 2019 (2019).
Borresen, S. W. et al. Adrenal insufficiency is seen in more than one-third of patients during ongoing low-dose prednisolone treatment for rheumatoid arthritis. Eur. J. Endocrinol. 177, 287–295 (2017).
Philips, A. et al. Antagonism between Nur77 and glucocorticoid receptor for control of transcription. Mol. Cell. Biol. 17, 5952–5959 (1997).
Yamamori, E. et al. Molecular mechanisms for corticotropin-releasing hormone gene repression by glucocorticoid in BE(2)C neuronal cell line. Mol. Cell. Endocrinol. 264, 142–148 (2007).
Newton, R., Shah, S., Altonsy, M. O. & Gerber, A. N. Glucocorticoid and cytokine crosstalk: feedback, feedforward, and co-regulatory interactions determine repression or resistance. J. Biol. Chem. 292, 7163–7172 (2017).
Ito, K. et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N. Engl. J. Med. 352, 1967–1976 (2005).
Devereux, G. et al. Effect of theophylline as adjunct to inhaled corticosteroids on exacerbations in patients with copd: a randomized clinical trial. JAMA 320, 1548–1559 (2018).
Liberman, A. C., Druker, J., Perone, M. J. & Arzt, E. Glucocorticoids in the regulation of transcription factors that control cytokine synthesis. Cytokine Growth Factor Rev. 18, 45–56 (2007).
Franchimont, D. et al. Inhibition of Th1 immune response by glucocorticoids: dexamethasone selectively inhibits IL-12-induced Stat4 phosphorylation in T lymphocytes. J. Immunol. 164, 1768–1774 (2000).
Ramirez, F., Fowell, D. J., Puklavec, M., Simmonds, S. & Mason, D. Glucocorticoids promote a Th2 cytokine response by CD4+ T cells in vitro. J. Immunol. 156, 2406–2412 (1996).
Schleimer, R. P., Jacques, A., Shin, H. S., Lichtenstein, L. M. & Plaut, M. Inhibition of T cell-mediated cytotoxicity by anti-inflammatory steroids. J. Immunol. 132, 266–271 (1984).
Migliorati, G. et al. Glucocorticoid-induced apoptosis of natural killer cells and cytotoxic T lymphocytes. Pharmacol. Res. 26, 26–27 (1992).
Cupps, T. R., Gerrard, T. L., Falkoff, R. J., Whalen, G. & Fauci, A. S. Effects of in vitro corticosteroids on B cell activation, proliferation, and differentiation. J. Clin. Invest. 75, 754–761 (1985).
Lill-Elghanian, D., Schwartz, K., King, L. & Fraker, P. Glucocorticoid-induced apoptosis in early B cells from human bone marrow. Exp. Biol. Med. 227, 763–770 (2002).
Zhou, J. et al. Glucocorticoids inhibit degranulation of mast cells in allergic asthma via nongenomic mechanism. Allergy 63, 1177–1185 (2008).
Franchimont, D. Overview of the actions of glucocorticoids on the immune response: a good model to characterize new pathways of immunosuppression for new treatment strategies. Ann. N. Y. Acad. Sci. 1024, 124–137 (2004).
Zhou, J. Y. et al. Corticosterone exerts immunostimulatory effects on macrophages via endoplasmic reticulum stress. Br. J. Surg. 97, 281–293 (2010).
Barczyk, K. et al. Glucocorticoids promote survival of anti-inflammatory macrophages via stimulation of adenosine receptor A3. Blood 116, 446–455 (2010).
McColl, A. et al. Glucocorticoids induce protein S-dependent phagocytosis of apoptotic neutrophils by human macrophages. J. Immunol. 183, 2167–2175 (2009).
Cavalcanti, D. M. et al. Endogenous glucocorticoids control neutrophil mobilization from bone marrow to blood and tissues in non-inflammatory conditions. Br. J. Pharmacol. 152, 1291–1300 (2007).
Filep, J. G., Delalandre, A., Payette, Y. & Foldes-Filep, E. Glucocorticoid receptor regulates expression of L-selectin and CD11/CD18 on human neutrophils. Circulation 96, 295–301 (1997).
Mogensen, T. H., Berg, R. S., Paludan, S. R. & Ostergaard, L. Mechanisms of dexamethasone-mediated inhibition of Toll-like receptor signaling induced by Neisseria meningitidis and Streptococcus pneumoniae. Infect. Immun. 76, 189–197 (2008).
Sivertson, K. L., Seeds, M. C., Long, D. L., Peachman, K. K. & Bass, D. A. The differential effect of dexamethasone on granulocyte apoptosis involves stabilization of Mcl-1L in neutrophils but not in eosinophils. Cell. Immunol. 246, 34–45 (2007).
Khoury, P. et al. Glucocorticoid-induced eosinopenia in humans can be linked to early transcriptional events. Allergy 73, 2076–2079 (2018).
Chen, F. et al. Glucocorticoid induced osteoblast apoptosis by increasing E4BP4 expression via up-regulation of Bim. Calcif. Tissue Int. 94, 640–647 (2014).
Swanson, C., Lorentzon, M., Conaway, H. H. & Lerner, U. H. Glucocorticoid regulation of osteoclast differentiation and expression of receptor activator of nuclear factor-κB (NF-κB) ligand, osteoprotegerin, and receptor activator of NF-κB in mouse calvarial bones. Endocrinology 147, 3613–3622 (2006).
Humphrey, E. L., Williams, J. H., Davie, M. W. & Marshall, M. J. Effects of dissociated glucocorticoids on OPG and RANKL in osteoblastic cells. Bone 38, 652–661 (2006).
Huang, Y., Cai, G. Q., Peng, J. P. & Shen, C. Glucocorticoids induce apoptosis and matrix metalloproteinase-13 expression in chondrocytes through the NOX4/ROS/p38 MAPK pathway. J. Steroid Biochem. Mol. Biol. 181, 52–62 (2018).
Braun, T. P. & Marks, D. L. The regulation of muscle mass by endogenous glucocorticoids. Front. Physiol. 6, 12 (2015).
Troncoso, R. et al. Dexamethasone-induced autophagy mediates muscle atrophy through mitochondrial clearance. Cell Cycle 13, 2281–2295 (2014).
Hardy, R. S. et al. Differential expression, function and response to inflammatory stimuli of 11β-hydroxysteroid dehydrogenase type 1 in human fibroblasts: a mechanism for tissue-specific regulation of inflammation. Arthritis Res. Ther. 8, R108 (2006).
Durmus, M. et al. The effects of single-dose dexamethasone on wound healing in rats. Anesth. Analg. 97, 1377–1380 (2003).
Pitzalis, C. et al. Corticosteroids inhibit lymphocyte binding to endothelium and intercellular adhesion: an additional mechanism for their anti-inflammatory and immunosuppressive effect. J. Immunol. 158, 5007–5016 (1997).
Pitzalis, C., Pipitone, N. & Perretti, M. Regulation of leukocyte-endothelial interactions by glucocorticoids. Ann. N. Y. Acad. Sci. 966, 108–118 (2002).
Elftman, M. D., Norbury, C. C., Bonneau, R. H. & Truckenmiller, M. E. Corticosterone impairs dendritic cell maturation and function. Immunology 122, 279–290 (2007).
The authors acknowledge the support of the Versus Arthritis Research into Inflammatory Arthritis Centre collaboration at the University of Birmingham.
The authors declare no competing interests.
Peer review information
Nature Reviews Rheumatology thanks J. Tuckermann, L. Franco and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Hardy, R.S., Raza, K. & Cooper, M.S. Therapeutic glucocorticoids: mechanisms of actions in rheumatic diseases. Nat Rev Rheumatol 16, 133–144 (2020). https://doi.org/10.1038/s41584-020-0371-y
This article is cited by
Accrual of organ damage in Behçet’s syndrome: trajectory, associated factors, and impact on patients’ quality of life over a 2-year prospective follow-up study
Arthritis Research & Therapy (2022)
Nature Reviews Rheumatology (2022)
Cellular and Molecular Life Sciences (2022)
Current Rheumatology Reports (2022)
Ultrasound-guided genicular nerve block a new treatment in rheumatology for knee osteoarthritis pain
Rheumatology International (2022)